26 RESULTS
Go to another page:
COMMENT My colleagues and I are encouraged by attention directed at modifiers of innate immune activity for treatment of AD. However, we urge caution in the application of anti-immune (including anti-TREM2) treatments in humans. The proposed Phase 1 work should ...
COMMENT We understand Dr. Rebeck’s comment and his (and editorialists Drs. Hershey’s and Lipton’s) evident desire to consider all possibilities before abandoning NSAIDs altogether for prevention of AD. We offer two caveats, however: 1) We question whether it’s ...
COMMENT Caution is warranted here. We must not jump to the conclusion, based on this data, that the "inflammatory" or microglial response is the cause of destruction. It accompanies destruction, to be sure, but there are reasons to wonder whether the ...
COMMENT The culprit may indeed be air pollutants. But there's a potential confounder that, I would suggest, is quite plausible. Who wants to live near a major highway? Not me, nor most people I would think. Money buys privilege, so real property values near ...
COMMENT This appears to be a carefully conceived and conducted prospective observational study of the relation between low- vs. higher-usage of the common statin drugs and incident Alzheimer’s dementia (AD). The study incorporates some clever design features, e.g ...
COMMENT This study is commendable as a trial of a "repurposed" NSAID that had otherwise lost its clinical relevance. The trial showed both formal efficacy and quality-of-life benefits in patients with a rare but lethal inherited syndrome that leads to ...
COMMENT The absence of clinical benefits is disappointing, but not surprising at this point, and the adverse events (AEs) are disconcerting. Notwithstanding the AEs, I agree with the investigators' speculation that earlier interventions may be required for ...
COMMENT The primary outcome data from the reaZin study appear to be consistent with the proposed action of the intervention. The three cognitive and functional measures used for the series of secondary outcomes are appropriate, but the small size of the sample ...
COMMENT Absence of proof is not proof of absence. The committee's conclusions reflect the current standards of evidence-based medicine as regards recommendations for interventions, including preventive interventions. By these standards, the field of AD ...
COMMENT CMS stands to benefit hugely from any successful development of efficacious interventions for prevention. They should be highly motivated to facilitate prevention research. We could start by clarifying that CMS will pay for clinical evaluation when the ...
COMMENT Two endpoints should not be a problem, if one of the endpoints is reduced incidence of dementia. Dementia by definition implies functional impairment, which fills the need for a second endpoint. john.breitner 0 ...
COMMENT If we have a chance to come back to methodologic dilemmas confronting Primary Prevention trials, it may be worth noting that it's possible to measure endpoints from trial populations that are very widely dispersed geographically. Think of ADAMS with ...
COMMENT My thoughts are that this as a very interesting approach. It capitalizes on our understandings of the populations of neurons that are (and are not) vulnerable to degeneration in Parkinson's disease, and uses relatively recent but now well developed ...
COMMENT Further evidence that RECENT blood pressure measures are not related to occurrence of AD or cognitive decline. Earlier reports suggested that, by contrast, midlife blood pressure is a potent predictor of same. What is needed is resolution of the question ...
COMMENT This, and other important work in a similar vein, suggests that "Alzheimerization" of brain occurs at least a decade prior to occurrence of symptoms. If clinically practical early markers for this process can be discovered, it would enable the ...
Go to another page:
